Hypoglycaemic activity of biosynthesized copper oxide nanoparticles in alloxan‐induced diabetic Wister rats
Endocrinology, Diabetes & Metabolism · 2023
DOI: 10.1002/edm2.423 ↗At a glance
Journal article in Endocrinology, Diabetes & Metabolism, 2023. Written by Maimuna Bello Umar and 6 co-authors. Institution: Department of Biochemistry, Federal University of Technology, Minna, Nigeria. Major MEDLINE topics: Diabetes Mellitus, Experimental, Nanoparticles. Cited 19 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Diabetes mellitus (DM) is a metabolic disorder that affects the body's ability to produce or use insulin. This study evaluated the hypoglycaemic activity of biosynthesized copper oxide nanoparticles (CuO‐NPs) in alloxan‐induced diabetic Wister rats.
Methods
CuO‐NPs were synthesized via the green route and characterized using different analytical tools. Diabetes was induced intraperitoneally using 90 mg/kg body weight of alloxan monohydrate in albino rats. Thirty (30) rats were randomly divided into 5 groups of 6 rats each and orally treated for 21 days. Groups I and II were treated with 300 mg/kg bwt Cereus hildmannianus extract and CuO‐NPs, respectively. Groups III and IV received 5 mg/kg bwt of Glibenclamide and 2 mL of normal saline, respectively, while Group V was left untreated as the diabetic control. Blood glucose (BG) levels and body weight changes were monitored at 3‐ and 7‐day intervals, respectively, throughout 21‐day treatment period. Lipid profiles, enzyme assays and histopathological studies of the liver were also carried out.
Results
Spheroidal tenorite phase of CuO‐NPs with a crystallite size of 62.57 nm, surface area (20.64 m 2 /g) and a UV‐maximum absorption at 214.27 nm was formed. The diabetic rats treated with 300 mg/kg bwt CuO‐NPs had the highest BG lowering ability (from 482.75 ± 27.70 to 124.50 ± 2.50 mg/dL). A significant difference ( p < 0.05) in weight gain and serum enzymes was also observed in the CuO‐NPs treated group compared with other groups. The CuO‐NPs‐treated group had a significant increase ( p < 0.05) in HDL‐cholesterol and a decrease in total cholesterol, triglycerides, LDL‐cholesterol and VLDL‐cholesterol compared with other groups.
Conclusion
The green synthesized CuO‐NPs nanoparticles significantly reduced ( p < 0.05) blood glucose levels in rats and other associated indices and could serve as drug lead in the treatment of diabetes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry, Federal University of Technology, Minna, Nigeria.
- Department of Biotechnology, University of the Western Cape, Bellville, South Africa.
- Department of Chemistry, Federal University of Technology, Minna, Nigeria.
ORCID profiles: Augustine Innalegwu Daniel
Cite
APA
Umar, M. B., Daniel, A. I., Tijani, J. O., Akinleye, R. O., Smith, E., Keyster, M., & Klein, A. (2023). Hypoglycaemic activity of biosynthesized copper oxide nanoparticles in alloxan‐induced diabetic Wister rats. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.423
Vancouver
Umar MB, Daniel AI, Tijani JO, Akinleye RO, Smith E, Keyster M, et al. Hypoglycaemic activity of biosynthesized copper oxide nanoparticles in alloxan‐induced diabetic Wister rats. Endocrinology, Diabetes & Metabolism. 2023. doi:10.1002/edm2.423
BibTeX
@article{Umar2023,
author = {Umar, Maimuna Bello and Daniel, Augustine Innalegwu and Tijani, Jimoh Oladejo and Akinleye, Rebecca Olufemi and Smith, Enriquay and Keyster, Marshall and Klein, Ashwil},
title = {Hypoglycaemic activity of biosynthesized copper oxide nanoparticles in alloxan‐induced diabetic Wister rats},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2023},
doi = {10.1002/edm2.423}
}
EUVIMED